Published on 25/12/2025
Designing Effective Strategies for Global Sponsors to Include China in Clinical Trials
Introduction
Global sponsors increasingly recognize the strategic importance of including China in multinational clinical development programs. With its vast patient population, growing regulatory alignment, and expanding research infrastructure, China is now one of the most attractive regions for clinical trials. The National Medical Products Administration (NMPA) has reformed processes to align with International Council for Harmonisation (ICH) standards, particularly ICH E17 for multinational clinical trials (MRCTs). However, integrating China into global development requires careful planning to address regulatory, operational, and cultural challenges. This article explores how sponsors can design effective China-inclusive strategies to maximize trial efficiency, ensure compliance, and accelerate global submissions.
Background and Regulatory Framework
Historic Barriers to Inclusion
Historically, sponsors often excluded China from global trials due to long approval timelines under the former CFDA, limited site capacity, and concerns about data reliability. These barriers delayed access to innovative therapies for Chinese patients and required separate bridging studies.
Regulatory Reforms Supporting Inclusion
The establishment of the NMPA and adoption of ICH E17 MRCT guidelines transformed China’s trial environment. The introduction of a 60-day IND “silent approval” system, expanded site accreditation, and greater acceptance of multinational data
Case Example: Oncology MRCT
A multinational oncology sponsor included China in a Phase III MRCT for a targeted therapy. By aligning with NMPA requirements and including 400 Chinese patients, the sponsor avoided a separate bridging study, accelerating global approval timelines by nearly two years.
Core Clinical Trial Insights
Strategic Site Selection
Sponsors must evaluate Tier-1 and Tier-2 hospitals for inclusion. Tier-1 hospitals provide experienced investigators and infrastructure, while Tier-2 hospitals expand access to diverse populations. Site readiness, ethics review capacity, and patient recruitment potential are critical factors in site selection.
Patient Recruitment and Diversity
China offers unparalleled recruitment potential due to its large patient base. However, urban-centric recruitment creates gaps in diversity. Sponsors must design recruitment strategies that include rural hospitals, minority populations, and underrepresented groups to meet global diversity expectations.
Regulatory Engagement with NMPA
Early and continuous engagement with the NMPA is vital. Sponsors should conduct pre-IND meetings, seek clarification on inclusion criteria, and align protocols with NMPA expectations. Mid-trial consultations ensure compliance with evolving regulations, particularly data localization and pharmacovigilance.
Operational Role of CROs
Local and global CRO partnerships are critical to managing China-inclusive trials. CROs provide expertise in site training, ethics submissions, pharmacovigilance, and data management. Hybrid CRO models combine global trial oversight with localized operational knowledge.
Data Localization and IT Infrastructure
China’s data localization laws require local storage of trial data and patient information. Sponsors must establish validated local IT systems for trial master files (TMFs), electronic data capture (EDC), and pharmacovigilance reporting. Cross-border data transfers require regulatory approvals.
Integration of China Data into Global Submissions
The NMPA accepts multinational trial data if Chinese patients are adequately represented. Including China early in MRCTs ensures global submissions (FDA, EMA, PMDA) incorporate Chinese data seamlessly, reducing the need for bridging studies and accelerating approval timelines.
Best Practices & Preventive Measures
Sponsors should plan China-inclusive trials early in global development. Best practices include:
✔️ Aligning protocols with ICH E17 and NMPA requirements
✔️ Engaging CROs with strong China operations
✔️ Expanding site networks beyond Tier-1 hospitals
✔️ Addressing data localization through local IT infrastructure
✔️ Training investigators in global GCP standards
✔️ Proactive regulatory engagement with the NMPA and ethics committees
These practices mitigate risks and ensure smooth integration of China into global programs.
Scientific & Regulatory Evidence
China’s reforms align with ICH E17 MRCT guidelines, ICH E6(R2) GCP, and WHO GCP. Comparative analysis shows NMPA requirements increasingly converge with FDA and EMA expectations, particularly regarding data integrity and diversity. The 2019 Drug Administration Law strengthened pharmacovigilance and inspection readiness, further aligning China with global standards.
Special Considerations
Special attention is required for rare disease, pediatric, and oncology trials in China, where patient recruitment and ethics oversight may be more complex. Cultural and linguistic diversity also necessitates tailored informed consent materials and patient engagement strategies.
When Sponsors Should Seek Regulatory Advice
Sponsors should seek regulatory advice from the NMPA when designing MRCT protocols, determining Chinese patient numbers, or planning data integration strategies. Pre-IND and mid-trial consultations help clarify expectations and reduce approval delays.
Case Studies
Case Study 1: Rare Disease MRCT Strategy
A multinational sponsor included 100 Chinese patients in a global rare disease trial. By aligning with NMPA and HGRAC requirements, the sponsor avoided a separate bridging study and achieved simultaneous FDA, EMA, and NMPA approvals, expediting patient access worldwide.
Case Study 2: CRO-Led Site Expansion
A sponsor conducting a cardiovascular MRCT relied on a hybrid CRO model to expand recruitment into Tier-2 hospitals. The approach improved patient diversity, met global regulator expectations, and ensured compliance with NMPA inspection standards.
FAQs
1. Why should global sponsors include China in clinical trials?
Including China provides access to large patient populations, accelerates recruitment, and ensures global submissions incorporate Chinese data.
2. What reforms support China-inclusive strategies?
NMPA reforms include the silent approval system, ICH E17 adoption, expanded site accreditation, and global data acceptance.
3. How does data localization affect China-inclusive trials?
Data must be stored domestically, requiring local IT infrastructure and regulatory approvals for cross-border transfers.
4. How do CROs support global sponsors in China?
CROs manage site readiness, ethics submissions, pharmacovigilance, and inspection preparedness, ensuring compliance with NMPA expectations.
5. Can Chinese trial data be used in global submissions?
Yes, if Chinese patients are adequately represented in MRCTs. This reduces the need for bridging studies and expedites global approvals.
6. What best practices ensure success in China-inclusive trials?
Early regulatory engagement, strong CRO partnerships, diverse site selection, and harmonized protocols aligned with ICH and NMPA standards.
Conclusion & Call-to-Action
China’s integration into global clinical trials has transformed from a barrier to a strategic advantage for sponsors. With regulatory reforms, strong patient recruitment potential, and harmonization with ICH standards, China is now central to multinational development programs. Sponsors must invest in regulatory engagement, CRO partnerships, and data infrastructure to successfully design China-inclusive strategies. Organizations planning global trials should proactively include China to accelerate approvals and expand access to innovative therapies worldwide.